Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07567846 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
A Phase 1 study, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
NCT07567846 is a Phase 1 study that is actively recruiting participants, run by Genentech. The registered enrollment target is 260 participants.
The verdict
NCT07567846, a Phase 1 study, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Interventions
- DRUG GDC-1261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-04-29 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07567846
The ClinicalTrials.gov registry entry for NCT07567846 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-1261 is the first listed.
NCT07567846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07567846 about?
NCT07567846 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer". The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
What is the current status of trial NCT07567846?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2026-04-29. Estimated completion is 2027-12-30.
What interventions are being tested in trial NCT07567846?
The interventions under investigation include: GDC-1261 (DRUG).
Who is sponsoring clinical trial NCT07567846?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.